TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Sun Pharmaceutical Industries Ltd.
SUNPHARMALarge CapNSEBSE
Healthcare · Healthcare
₹1,922.00up 8.70up 0.45 percentas of 28 Aug 2026
Book value ₹348.82Div yield 0.83%
Key metrics
- Market Cap
- 4,60,661.46 ₹ cr
- P/E
- 41.52 x
- P/B
- 5.51 x
- ROE
- 39.47%
- ROCE
- 48.90%
- Debt to Equity
- 0.35 x
- Net Margin
- 14.45%
- Dividend Yield
- 0.83%
- Revenue Growth (YoY)
- 10.46%
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- ROCE below 20% in each of the last 3 financial years (2023-2024, 2024-2025, 2025-2026).
- Revenue grew year-on-year in each of the last 3 years.
- Net margin declined year-on-year in 1 of the last 3 years.
- Promoter holding 54.5% (pledge data not available).
- Debt-to-equity 0.35 — above the Healthcare median of 0.31.
SUNPHARMA
₹1,922.00up 0.45 percent
EOD Synced: 28 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatStable Return Franchise
14.27%ROCE
ROE: 13.74%·P/B: 5.51x
2. Forensic Health & SolvencyPiotroski 4/9 · Adequate Health
4/9Piotroski Score
Altman: 8.8 (Safe Zone)
3. Valuation & DCF Spread-55.6% Valuation Premium
₹854DCF Fair Value
CMP: ₹1,922.0
4. Ownership & GovernanceClean Promoter Holding
54.48%Promoter Stake
Pledged: 0.0%·Inst: 27.38%
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #7 of 46 in HealthcareQVGM 58/100
Quality (Q)84
ROE, ROCE, Margins & Cash Conversion
Value (V)41
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)42
3Y Sales & EPS Compounded Growth
Momentum (M)62
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #7 of 46 in Healthcare
Valuation
Moderate41/100
P/E Ratio:41.52x
P/B Ratio:5.51x
Dividend Yield:0.83%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Moderate42/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Strong84/100
ROE:13.7%
ROCE:14.3%
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Moderate44/100
Piotroski F-Score:4/9
Altman Z-Score:8.82
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Moderate62/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹1,563.30
From 52W High-3.95%
52-Week High₹2,001.10
Valuation MultiplesCash Flow & Yield
PEG Ratio3.52
Earnings Yield27.72%
Price / FCF881.33
FCF Yield0.11%
Payout Ratio3.00%
Net-Net Ratio-0.60
Solvency & SafetyPiotroski & Altman
Piotroski F-Score4/9
Altman Z-Score8.82
Graham Number₹2,044.93
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▼ 1.40%
DII Stake:▲ +0.88%
OPM Margin:▼ 1.61%
Net Margin:▼ 1.15%
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | ▲ +4.71% | ▲ +10.46% | 11.19% | 10.03% | 11.78% |
| Net Profit Growth | ▲ +6.66% | ▲ +27.04% | 5.04% | 10.65% | 31.64% |
| EPS Growth | ▲ +10.09% | ▲ +10.57% | 5.03% | 11.81% | 13.51% |
Intrinsic Valuation Models & DCF Sensitivity
Institutional DCF & Intrinsic Valuation Studio — SUNPHARMA
2-Stage Discounted Cash Flow, Reverse DCF Implied Growth, and Benjamin Graham & Peter Lynch valuation benchmarks.
DCF Intrinsic Fair Value
₹909.0
Verdict:Overvalued (-52.7%)
Benjamin Graham Number
₹628.0
-67.3% vs CMPPeter Lynch Fair Value
₹251.7
-86.9% vs CMPReverse DCF Implied Growth
40.9% CAGR
Aggressive Expectations (Priced for Perfection)Valuation Spectrum PositioningCMP: ₹1,922.0
₹0 (Distress)CMP: ₹1,922DCF: ₹909Graham: ₹628
Scenario Calibration & Sensitivity Levers
Tune Discount Rate (WACC), 5-Year Growth, and Terminal Value to model bear, base, and bull cases.
Discount Rate (WACC)11.5%
Cost of Capital Hurdle
5-Year FCF Growth CAGR16.4%
Assumed stage-1 cash flow expansionTerminal Growth Rate4.5%
Long-term perpetual GDP growth rate5-Year Projected Cash Flow Schedule (₹ Cr)
| Projection Period | Growth Rate | Projected FCF | Discount Factor | Present Value |
|---|---|---|---|---|
| Year 1 | 16.4% | ₹10,444 | 0.8969 | ₹9,367 |
| Year 2 | 16.4% | ₹12,157 | 0.8044 | ₹9,778 |
| Year 3 | 16.4% | ₹14,151 | 0.7214 | ₹10,208 |
| Year 4 | 16.4% | ₹16,471 | 0.6470 | ₹10,657 |
| Year 5 | 16.4% | ₹19,172 | 0.5803 | ₹11,125 |
2D Sensitivity Matrix (WACC vs Terminal Growth Rate)
Click any cell to apply WACC & terminal growth scenario. Values in ₹ / share.| WACC \ g(Terminal) | 3.0% | 4.0% | 4.5% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | ₹956 -50% | ₹1086 -43% | ₹1169 -39% | ₹1268 -34% | ₹1541 -20% |
| 11.0% | ₹830 -57% | ₹924 -52% | ₹982 -49% | ₹1050 -45% | ₹1225 -36% |
| 11.5% | ₹779 -59% | ₹860 -55% | ₹909 -53% | ₹966 -50% | ₹1110 -42% |
| 12.0% | ₹733 -62% | ₹803 -58% | ₹846 -56% | ₹894 -53% | ₹1015 -47% |
| 13.0% | ₹655 -66% | ₹709 -63% | ₹741 -61% | ₹777 -60% | ₹865 -55% |
Discounted cash flow (DCF) and valuation models are quantitative projections based on user-supplied assumptions — not a forecast, not a guarantee of future performance, and not SEBI-registered investment advice. Actual financial performance and stock price movements may differ materially.
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E41.52current
ReportedComputed, approximate
P/B5.51current
ReportedComputed, approximate
The dashed line is computed from historical close price divided by the most recently reported annual EPS or book value — not IndianAPI's own figure, which only ever gives a single current reading with no history behind it. Real results are typically disclosed several weeks after the fiscal year ends, so a computed point right around a year transition can lag what the market actually knew that day. The solid line is the real reported figure.
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | 41.52 | 5.51 |
Analyst Consensus, Price Targets & Forecasts
Analyst Consensus & Recommendations
Aggregated institutional equity research ratings · 31 Aug 2026
Buy(2.00 / 5)
Strong Buy:8
Buy:21
Hold:1
Sell:2
Strong Sell:1
Coverage: 33 contributing analystsScale: 1 (Strong Buy) – 5 (Strong Sell)
Ratings shown are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
Moderate risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:20.13%
Analyst Price Targets
12-month forward price consensus · 31 Aug 2026
Upside: +12.02%
Mean Target₹2,153.00vs CMP ₹1,922.00
High Target₹2,400.00+24.9% max upside
Low Target₹1,830.00-4.8% downside
Median Target₹2,150.0033 estimates
Low: ₹1,830.00Mean: ₹2,153.00High: ₹2,400.00
Mean Target Current Price (₹1,922.00)
Price targets are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2024EConsensus
Mean Estimate
₹11.53
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹9.74
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹9.90
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹10.79
Low:—
High:—
FY2025EConsensus
Mean Estimate
₹11.80
Low:—
High:—
FY2025E6 Analysts
Mean Estimate
₹12.70
Low:—
High:—
FY2025E6 Analysts
Mean Estimate
₹13.41
Low:—
High:—
FY2025E6 Analysts
Mean Estimate
₹10.52
Low:—
High:—
FY2026E8 Analysts
Mean Estimate
₹11.30
Low:—
High:—
FY2026E6 Analysts
Mean Estimate
₹13.00
Low:—
High:—
FY2026E7 Analysts
Mean Estimate
₹16.03
Low:—
High:—
FY2026E6 Analysts
Mean Estimate
₹12.91
Low:—
High:—
FY2027E3 Analysts
Mean Estimate
₹12.69
Low:₹11.00
High:₹13.00
FY2027E8 Analysts
Mean Estimate
₹12.95
Low:—
High:—
FY2027E3 Analysts
Mean Estimate
₹13.50
Low:₹11.00
High:₹16.00
FY2027E3 Analysts
Mean Estimate
₹13.88
Low:₹13.00
High:₹14.00
FY2028E1 Analysts
Mean Estimate
₹14.11
Low:₹14.00
High:₹14.00
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2024 Forecast | ₹11.53 | — | — | — |
| FY2024 Forecast | ₹9.74 | — | — | — |
| FY2024 Forecast | ₹9.90 | — | — | — |
| FY2024 Forecast | ₹10.79 | — | — | — |
| FY2025 Forecast | ₹11.80 | — | — | — |
| FY2025 Forecast | ₹12.70 | — | — | 6 |
| FY2025 Forecast | ₹13.41 | — | — | 6 |
| FY2025 Forecast | ₹10.52 | — | — | 6 |
| FY2026 Forecast | ₹11.30 | — | — | 8 |
| FY2026 Forecast | ₹13.00 | — | — | 6 |
| FY2026 Forecast | ₹16.03 | — | — | 7 |
| FY2026 Forecast | ₹12.91 | — | — | 6 |
| FY2027 Forecast | ₹12.69 | ₹13.00 | ₹11.00 | 3 |
| FY2027 Forecast | ₹12.95 | — | — | 8 |
| FY2027 Forecast | ₹13.50 | ₹16.00 | ₹11.00 | 3 |
| FY2027 Forecast | ₹13.88 | ₹14.00 | ₹13.00 | 3 |
| FY2028 Forecast | ₹14.11 | ₹14.00 | ₹14.00 | 1 |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
Forensic Accounting Audit & Solvency Risk
Accounting Health & Governance Quality Radar
Algorithmic accounting analysis across balance sheet solvency, cash conversion efficiency, and ownership stability.
Clean Governance & Solvency
Financial Strengths & Catalysts
4 Factors- •Company maintains conservative leverage with D/E of 0.06x.
- •Strong cash generation: Operating Cash Flow is 109.6% of reported Net Profit.
- •High promoter holding of 54.5% with zero encumbrance / pledge.
- •High institutional backing: FIIs & DIIs hold a combined 27.4%.
Risk Factors & Watchouts
0 WatchoutsClean profile: No major debt, leverage, or working capital red flags detected.
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score4 / 9
● Moderate (Neutral)
Altman Z-Score8.82
● Safe Zone
Negligible risk of financial distress over the next 2 years.
Beneish M-Score-2.39
● Low Risk (Clean Accounting)
Cash flows closely match reported earnings with conservative accruals.
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
Accounting Flow:
Wall Street Cash Flow & Free Cash Flow (FCF) Cascade
FY26 (2025-2026)3-Stage institutional flow from reported earnings to owner Free Cash Flow and capital allocation
FCF Conversion Rate (FCF / PAT)
78.2%Healthy
Measures how much reported accounting profit turns into real liquid cash.
Free Cash Flow Margin
15.3%of Gross Revenue
Liquid cash retained per ₹100 of top-line revenue generated.
CapEx Reinvestment Rate
28.7%of Operating Cash
Portion of operating cash reinvested in future capacity and maintenance.
Reported Net Profit (PAT)₹11,479 CrInflow
11,479
+ D&A Non-Cash Charge₹2,938 CrAdd-back
2,938
Working Capital Adjustment-₹1,835 Cr- Tied Up
1,835
= Operating Cash Flow (CFO)₹12,582 CrOperating Cash
12,582
- Capital Expenditures (CapEx)-₹3,609 CrReinvestment
3,609
= Free Cash Flow (FCF)₹8,973 CrFree Cash Flow
8,973
- Dividends & Debt Repayment-₹2,525 CrCapital Return
2,525
= Net Change in Cash₹6,448 CrNet Balance
6,448
Multi-Year Historical FCF vs Reported PAT Trajectory:
Free Cash Flow (FCF) Reported Net Profit (PAT)
| Metric | 2014-201531 Mar 2015 | 2015-201631 Mar 2016 | 2016-201731 Mar 2017 | 2017-201831 Mar 2018 | 2018-201931 Mar 2019 | 2019-202031 Mar 2020 | 2020-202131 Mar 2021 | 2021-202231 Mar 2022 | 2022-202331 Mar 2023 | 2023-202431 Mar 2024 | 2024-202531 Mar 2025 | 2025-202631 Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | ₹29,065.91 | ₹32,837.50 | ₹33,498.14 | ₹38,654.49 | ₹43,885.68 | ₹48,496.85 | ₹52,578.44 | ₹58,462.04 |
| Operating profit | — | — | — | — | ₹3,687.70 | ₹4,708.38 | ₹2,146.62 | ₹3,577.67 | ₹9,092.35 | ₹10,016.93 | ₹11,903.93 | ₹12,292.44 |
| OPM | — | — | — | — | 12.69% | 14.34% | 6.41% | 9.26% | 20.72% | 20.65% | 22.64% | 21.03% |
| Net profit | — | — | — | — | ₹2,665.42 | ₹3,764.93 | ₹2,903.82 | ₹3,272.73 | ₹8,473.58 | ₹9,576.38 | ₹10,929.04 | ₹11,479.42 |
| EPS | — | — | — | — | 15.61 | 16.54 | 26.71 | 28.03 | 36.01 | 41.74 | 47.92 | 50.33 |
| Net margin | — | — | — | — | 9.17% | 11.47% | 8.67% | 8.47% | 19.31% | 19.75% | 20.79% | 19.64% |
| ROE | — | — | — | — | 6.44% | 8.32% | 6.25% | 6.82% | 15.13% | 15.04% | 15.13% | 13.74% |
| ROCE | 23.00% | 18.00% | 20.00% | 10.00% | 7.79% | 8.96% | 4.17% | 6.80% | 14.95% | 14.62% | 16.11% | 14.27% |
| Debt / equity | — | — | — | — | 0.25 | 0.18 | 0.08 | 0.03 | 0.12 | 0.05 | 0.03 | 0.06 |
Compounded growth (CAGR)
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Revenue | 11.19% | 10.03% | 11.78% | — |
| Net profit | 5.04% | 10.65% | 31.64% | — |
| EPS | 5.03% | 11.81% | 13.51% | — |
Each column only appears when 12 real reported years actually support it — never extrapolated from fewer.
Balance sheet
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | — | — | — | ₹64,693.81 | ₹68,252.46 | ₹67,666.73 | ₹69,807.77 | ₹80,743.59 | ₹85,499.65 | ₹92,100.58 | ₹1.09 L |
| Total liabilities | — | — | — | — | ₹23,284.75 | ₹22,988.01 | ₹21,203.95 | ₹21,796.55 | ₹24,748.21 | ₹21,832.90 | ₹19,882.56 | ₹25,215.13 |
| Total equity | — | — | — | — | ₹41,409.06 | ₹45,264.45 | ₹46,462.78 | ₹48,011.22 | ₹55,995.38 | ₹63,666.75 | ₹72,218.02 | ₹83,570.09 |
| Total debt | — | — | — | — | ₹10,514.36 | ₹8,314.88 | ₹3,868.58 | ₹1,290.30 | ₹6,885.87 | ₹3,273.67 | ₹2,362.19 | ₹4,627.32 |
| Cash | — | — | — | — | ₹165.86 | ₹790.83 | ₹3,000.35 | ₹2,676.94 | ₹4,370.23 | ₹2,442.57 | ₹3,296.95 | ₹5,501.03 |
| Current assets | — | — | — | — | ₹31,069.19 | ₹31,654.16 | ₹30,442.08 | ₹34,864.60 | ₹39,861.94 | ₹43,433.11 | ₹52,594.06 | ₹63,860.29 |
| Current liabilities | — | — | — | — | ₹17,339.62 | ₹15,706.43 | ₹16,145.63 | ₹17,208.45 | ₹19,906.38 | ₹16,983.77 | ₹18,194.21 | ₹22,622.04 |
| Inventory | — | — | — | — | ₹8,262.40 | ₹8,269.22 | ₹9,361.80 | ₹9,239.16 | ₹10,968.32 | ₹10,294.89 | ₹10,759.33 | ₹12,058.51 |
| Receivables | — | — | — | — | ₹8,900.67 | ₹9,433.29 | ₹9,104.23 | ₹10,513.93 | ₹11,489.29 | ₹11,302.97 | ₹13,122.51 | ₹15,562.19 |
| Payables | — | — | — | — | ₹4,147.87 | ₹4,093.73 | ₹3,973.66 | ₹4,489.76 | ₹5,681.52 | ₹5,653.30 | ₹6,184.34 | ₹7,333.80 |
| Net PP&E | — | — | — | — | ₹10,938.21 | ₹11,226.34 | ₹11,171.51 | ₹11,168.89 | ₹11,353.73 | ₹11,300.05 | ₹11,270.28 | ₹12,494.76 |
| Retained earnings | — | — | — | — | ₹37,286.34 | ₹39,278.50 | ₹40,562.04 | ₹41,609.60 | ₹47,574.20 | ₹54,118.50 | ₹61,825.79 | ₹69,840.95 |
Cash flow
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | — | — | — | ₹2,241.97 | ₹6,554.77 | ₹6,170.37 | ₹9,025.99 | ₹5,526.02 | ₹12,136.27 | ₹14,072.06 | ₹12,581.91 |
| Capital expenditure | — | — | — | — | ₹-3,212.82 | ₹-1,542.00 | ₹-1,170.13 | ₹-1,495.04 | ₹-2,085.58 | ₹-2,201.81 | ₹-2,128.58 | ₹-3,609.37 |
| Free cash flow | — | — | — | — | ₹-970.85 | ₹5,012.77 | ₹5,000.24 | ₹7,530.95 | ₹3,440.44 | ₹9,934.46 | ₹11,943.48 | ₹8,972.54 |
| OCF / net profit | — | — | — | — | 0.84 | 1.74 | 2.12 | 2.76 | 0.65 | 1.27 | 1.29 | 1.10 |
| FCF / Capex intensity | — | — | — | — | 11.05 | 4.70 | 3.49 | 3.87 | 4.75 | 4.54 | 4.05 | 6.17 |
Income statement detail
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | — | — | — | — | ₹19,827.15 | ₹22,366.23 | ₹22,985.63 | ₹26,244.06 | ₹31,113.21 | ₹35,666.41 | ₹39,630.53 | ₹44,475.24 |
| Cost of revenue | — | — | — | — | ₹9,238.76 | ₹10,471.27 | ₹10,512.51 | ₹12,410.43 | ₹12,772.47 | ₹12,830.44 | ₹12,947.91 | ₹13,986.80 |
| EBITDA | — | — | — | — | ₹5,440.95 | ₹6,761.16 | ₹4,226.57 | ₹5,721.41 | ₹11,621.78 | ₹12,573.72 | ₹14,479.32 | ₹15,230.29 |
| Income before tax | — | — | — | — | ₹3,810.20 | ₹5,009.59 | ₹2,799.37 | ₹4,481.32 | ₹9,408.43 | ₹11,087.89 | ₹13,752.13 | ₹15,118.88 |
| Interest expense | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax expense | — | — | — | — | ₹600.88 | ₹822.80 | ₹514.69 | ₹1,075.50 | ₹847.59 | ₹1,439.45 | ₹2,772.03 | ₹3,939.76 |
| D&A | — | — | — | — | ₹1,753.25 | ₹2,052.78 | ₹2,079.95 | ₹2,143.74 | ₹2,529.43 | ₹2,556.79 | ₹2,575.39 | ₹2,937.85 |
| EBITDA margin | — | — | — | — | 18.72% | 20.59% | 12.62% | 14.80% | 26.48% | 25.93% | 27.54% | 26.05% |
Financial ratios
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | — | — | — | — | 1.79 | 2.02 | 1.89 | 2.03 | 2.00 | 2.56 | 2.89 | 2.82 |
| Quick ratio | — | — | — | — | 1.32 | 1.49 | 1.31 | 1.49 | 1.45 | 1.95 | 2.30 | 2.29 |
| Interest coverage | — | — | — | — | — | — | — | — | — | — | — | — |
| Inventory days | 307.00 | 370.00 | 307.00 | 338.00 | 326.43 | 288.24 | 325.05 | 271.73 | 313.44 | 292.87 | 303.30 | 314.68 |
| Receivable days | 68.00 | 87.00 | 83.00 | 108.00 | 111.77 | 104.85 | 99.20 | 99.28 | 95.56 | 85.07 | 91.10 | 97.16 |
| Payable days | 178.00 | 207.00 | 197.00 | 234.00 | 163.87 | 142.70 | 137.97 | 132.05 | 162.36 | 160.82 | 174.34 | 191.38 |
| Cash conversion cycle | 197.00 | 251.00 | 193.00 | 212.00 | 274.33 | 250.40 | 286.28 | 238.96 | 246.64 | 217.11 | 220.07 | 220.46 |
| Working capital days | -7.00 | 37.00 | -4.00 | -31.00 | 31.00 | 51.00 | 51.00 | 47.00 | 40.00 | 55.00 | 65.00 | 54.00 |
| Fixed asset turnover | — | — | — | — | 2.66 | 2.93 | 3.00 | 3.46 | 3.87 | 4.29 | 4.67 | 4.68 |
| ROA | — | — | — | — | 4.12% | 5.52% | 4.29% | 4.69% | 10.49% | 11.20% | 11.87% | 10.55% |
| ROIC | — | — | — | — | 6.00% | 7.45% | 3.70% | 5.83% | 14.14% | 13.51% | 13.33% | 10.99% |
| Gross margin | — | — | — | — | 68.21% | 68.11% | 68.62% | 67.89% | 70.90% | 73.54% | 75.37% | 76.08% |
DuPont 3-Stage ROE Factor Decomposition
Deconstructing Return on Equity into Profitability, Asset Efficiency, and Financial Leverage
High Quality Moat (Margin Driven, Low Debt Risk)FY2025-2026
Net marginProfitability
19.64%
Net Profit generated per ₹100 of revenue (Profitability)
×
Asset turnoverEfficiency
0.54
Revenue generated per ₹1 of total assets (Capital Efficiency)
×
Equity multiplierLeverage
1.30
Total assets supported per ₹1 of shareholder equity (Leverage)
=
Implied DuPont ROEFinal Output
13.74%
Reported: 13.74%
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 07 Jul 2026 | dividend | 500% |
| 05 Feb 2026 | dividend | 1100% | |
| 2025 | 07 Jul 2025 | dividend | 550% |
| 06 Feb 2025 | dividend | 1050% | |
| 2024 | 12 Jul 2024 | dividend | 500% |
| 09 Feb 2024 | dividend | 850% | |
| 2023 | 28 Jul 2023 | dividend | 400% |
| 08 Feb 2023 | dividend | 750% | |
| 2022 | 22 Aug 2022 | dividend | 300% |
| 10 Feb 2022 | dividend | 700% | |
| 2021 | 25 Aug 2021 | dividend | 200% |
| 10 Feb 2021 | dividend | 550% | |
| 2020 | 21 Aug 2020 | dividend | 100% |
| 18 Feb 2020 | dividend | 300% | |
| 2019 | 22 Aug 2019 | dividend | 275% |
| 22 Aug 2019 | dividend | 275% | |
| 2018 | 19 Sept 2018 | dividend | 200% |
| 2017 | 20 Sept 2017 | dividend | 350% |
| 2016 | 10 Sept 2016 | dividend | 100% |
| 2015 | 24 Oct 2015 | dividend | 300% |
| 2014 | 13 Sept 2014 | dividend | 150% |
| 2013 | 23 Sept 2013 | dividend | 250% |
| 30 Jul 2013 | bonus | 1:1 | |
| 2012 | 16 Aug 2012 | dividend | 425% |
| 2011 | 06 Sept 2011 | dividend | 350% |
| 2010 | 26 Nov 2010 | split | 1:5 |
| 14 Sept 2010 | dividend | 275% | |
| 2009 | 25 Aug 2009 | dividend | 275% |
| 2008 | 27 Aug 2008 | dividend | 210% |
| 2007 | 16 Mar 2007 | dividend | 135% |
| 2006 | 08 Sept 2006 | dividend | 110% |
Dividend Intelligence & Capital Return History
Historical cash payout track record across 15 dividend distributions
Latest Year DPS:₹16.00
Yield on CMP:0.83%
3Y Dividend CAGR:+11.6%
Annual Dividend Payout Progression (Per Share)Total Cumulative DPS: ₹81.25
₹16.0
2026
₹16.0
2025
₹13.5
2024
₹11.5
2023
₹10.0
2022
₹7.5
2021
₹4.0
2020
₹2.8
2019
| Ex-Date | Amount (Per Share) | Dividend Type |
|---|---|---|
| 07 Jul 2026 | ₹5.00 | Final |
| 05 Feb 2026 | ₹11.00 | Interim |
| 07 Jul 2025 | ₹5.50 | Final |
| 06 Feb 2025 | ₹10.50 | Interim |
| 12 Jul 2024 | ₹5.00 | Final |
| 09 Feb 2024 | ₹8.50 | Interim |
| 28 Jul 2023 | ₹4.00 | Final |
| 08 Feb 2023 | ₹7.50 | Interim |
| 19 Aug 2022 | ₹3.00 | Final |
| 09 Feb 2022 | ₹7.00 | Interim |
| 23 Aug 2021 | ₹2.00 | Final |
| 09 Feb 2021 | ₹5.50 | Interim |
| 19 Aug 2020 | ₹1.00 | Final |
| 17 Feb 2020 | ₹3.00 | Interim |
| 20 Aug 2019 | ₹2.75 | Final |
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
HealthcareCompare Peers in Studio
Market Cap4,60,661.46 ₹ cr
Beats 100% of 65 industry peers · median 21,553.63 ₹ cr
P/E41.52 x
Beats 38% of 60 industry peers · median 51.05 x
P/B5.51 x
Beats 45% of 62 industry peers · median 6.18 x
ROE39.47%
Beats 98% of 65 industry peers · median 14.13%
ROCE48.90%
Beats 98% of 65 industry peers · median 16.38%
Debt to Equity0.35 x
Beats 58% of 65 industry peers · median 0.31 x
Net Margin14.45%
Beats 71% of 65 industry peers · median 13.15%
Dividend Yield0.83%
Beats 75% of 53 industry peers · median 0.42%
Revenue Growth (YoY)10.46%
Beats 22% of 64 industry peers · median 19.32%
| Company | Market Cap ▼ | P/E | P/B |
|---|---|---|---|
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.88 L | 79.00 | 20.38 |
Apollo Hospitals Enterprise Ltd.APOLLOHOSP | ₹1.27 L | 65.49 | 13.41 |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.16 L | 23.78 | 4.42 |
Cipla Ltd.CIPLA | ₹1.14 L | 29.66 | 3.34 |
Laurus Labs Ltd.LAURUSLABS | ₹1.05 L | 117.32 | 19.65 |
Peers are chosen strictly by industry classification. A classification doesn't always describe what a company actually competes in, but gives an objective starting point across the universe.
Regulatory Filings & Market Intelligence
Corporate Filings & Document Vault
SEBI LODR VerifiedAudited Annual Reports, Investor Decks, Earnings Concall Transcripts, and Board Resolutions for Sun Pharmaceutical Industries Ltd. (SUNPHARMA)
Indexed Documents5 Filings
Latest Disclosure04 Aug 2026
Secretarial Filing04 Aug 2026
Sun Pharmaceutical Industries Ltd: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015
Shareholding12 Jul 2026
Sun Pharmaceutical Industries Ltd: Quarterly Statement of Shareholding Pattern filed with NSE/BSE
Press Release15 Jun 2026
Sun Pharmaceutical Industries Ltd: Press Release: Business Updates and New Strategic Initiatives
Investor Deck09 Jun 2026
Sun Pharmaceutical Industries Ltd: Investor Presentation on Q4 Financial Results and Growth Outlook
News
- IndianAPIStock market today: Gift Nifty hints a gap-down start; eight-day trading stocks to buy on Monday, 31 August
Indian stock market indices, the Sensex and the Nifty 50, are expected to open lower on 31 August due to weak global cues. Geopolitical tensions between the US and Iran may impact energy prices. Key macroeconomic events include India's GDP data and US non-farm payrolls this week.
- IndianAPIAfter the lottery win: why Dr Reddy’s may be doing much more in its laboratories
The pharmaceutical company rode one copycat drug to record profits. Now, co-chairman G.V. Prasad has to prove the company can grow without it. Biosimilars and innovation may hold the answer.
- IndianAPISBI has 5-6 M&A deals in pipeline, eyes 20% share of ₹2 trillion market
The deals pursued by SBI are largely driven by technology and industry led.
- IndianAPISBI has 5-6 M&A deals in pipeline, eyes 20% share of ₹2 trillion market
The deals pursued by SBI are largely driven by technology and industry led.
- IndianAPIGoldman Sachs names Chandresh Chheda as co-head of India investment banking
Goldman Sachs has appointed former JPMorgan executive Chandresh Chheda as managing director and co-head of India investment banking. His appointment comes as India’s IPO, ECM and M&A markets remain strong, with Goldman expanding its dealmaking franchise.
- IndianAPIGoldman Sachs names Chandresh Chheda as co-head of India investment banking
Goldman Sachs has appointed former JPMorgan executive Chandresh Chheda as managing director and co-head of India investment banking. His appointment comes as India’s IPO, ECM and M&A markets remain strong, with Goldman expanding its dealmaking franchise.
- IndianAPIHow Trump's tariffs are reshaping Indian pharma
US tariffs may not impact Indian pharma in the short term, but building replacement capacity on US soil remains cost-prohibitive for thin-margin producers. At the same time, a Deloitte survey reveals CXOs want to prioritize specialty expansion.
- IndianAPIHow Trump's tariffs are reshaping Indian pharma
US tariffs may not impact Indian pharma in the short term, but building replacement capacity on US soil remains cost-prohibitive for thin-margin producers. At the same time, a Deloitte survey reveals CXOs want to prioritize specialty expansion.
- IndianAPISun Pharma’s premium push cushions US generics pain in Q1, but valuations look full
India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.
- IndianAPISun Pharma’s premium push cushions US generics pain in Q1, but valuations look full
India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.
- IndianAPIStocks to watch: Maruti Suzuki, IOC, Tata Steel among shares in focus today; check list here
Stock market today: On Thursday, Sensex climbed 274 points, or 0.35%, to close at 77,928, while the Nifty 50 gained 67 points, or 0.28%, to settle at 24,317.
- IndianAPIStocks to watch: Maruti Suzuki, IOC, Tata Steel among shares in focus today; check list here
Stock market today: On Thursday, Sensex climbed 274 points, or 0.35%, to close at 77,928, while the Nifty 50 gained 67 points, or 0.28%, to settle at 24,317.
- IndianAPIMint Explainer: How can Indian drugmakers blunt the impact of Trump’s generic tariffs?
From local outsourcing and tech transfers to passing costs on to American consumers, pharmaceutical firms are weighing tactical options to protect their margins.
- IndianAPIMint Explainer: How can Indian drugmakers blunt the impact of Trump’s generic tariffs?
From local outsourcing and tech transfers to passing costs on to American consumers, pharmaceutical firms are weighing tactical options to protect their margins.
- IndianAPIShares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 24 July 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 24 July 2026 - Manappuram Finance, Eicher Motors, and Sun Pharmaceutical Industries shares.
- IndianAPIShares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 24 July 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 24 July 2026 - Manappuram Finance, Eicher Motors, and Sun Pharmaceutical Industries shares.
- IndianAPICipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
- IndianAPICipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
- IndianAPIStock recommendations for 6 July from MarketSmith India
MarketSmith India reveals its top stock recommendations for today, 6 July. Get expert insights into the best-performing stocks to guide your investment decisions.
- IndianAPIStock recommendations for 6 July from MarketSmith India
MarketSmith India reveals its top stock recommendations for today, 6 July. Get expert insights into the best-performing stocks to guide your investment decisions.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.